PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma

Hodgkin Lymphoma Clinical Trial

Official title:

A Randomized Phase II Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Patients With Intermediate Stage Hodgkin's Lymphoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00512980
• Other study ID #: PVAG-14 pilot
• Status: Terminated
• Phase: Phase 2
• First received: August 7, 2007
• Last updated: December 1, 2015
• Start date: August 2008

Study information

• Verified date: December 2015
• Source: University of Cologne
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 0
• Est. primary completion date: November 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Histologically confirmed diagnosis of Hodgkin's lymphoma

2. Stage

• Clinical Stage IA, IB, IIA with at least one of the risk factors a-d given below

• Clinical Stage IIB with one or both risk factors c-d given below risk factors:

• Large mediastinal mass (= 1/3 of the greatest thorax diameter as measured by chest x-ray)

• Extranodal involvement

• High erythrocyte sedimentation rate (= 50 mm/h in patients without B-symptoms, = 30 mm/h in patients with B-symptoms)

• Three or more involved lymph node areas

3. No prior therapy for Hodgkin's lymphoma (exception: pre-phase treatment with corticosteroids and vinca-alkaloids for a maximum of seven days may not preclude trial participation if clinically indicated and all staging examinations have been performed; all forms of prior radiotherapy preclude trial participation)

4. Age: 18-60 years

5. Signed informed consent with understanding of the study procedures and the investigational nature of the study

6. Patient agrees that personal data and tissue samples are provided to the GHSG (protection of privacy as defined by law will be ensured)

7. Life expectancy > 3 months according to investigator judgement.

Exclusion Criteria:

1. Incomplete diagnosis of stage of disease

2. Prior or concurrent disease which prevents treatment according to protocol In particular the following contraindications:

• Chronic obstructive pulmonary disease with global insufficiency

• Symptomatic coronary heart disease

• Cardiomyopathy or cardiac insufficiency (NYHA value of EF < 50% or FS < 25%)

• Serious uncontrolled hypertension

• Uncontrollable infection

• Leucocyte concentration < 3.000/mm3 or thrombocyte concentration < 100.000/mm3

• Creatinin clearance < 60 ml/min

• Bilirubin > 2 mg/dl or GPT > 100 U/l or GOT > 100 U/I (exception: elevated values of Hodgkin`s disease liver involvement)

• HIV-Infection according to HIV test

• Chronic or acute Hepatitis

3. HD as composite lymphoma

4. Prior chemotherapy or radiation

5. Malignant disease within the last 5 years (exceptions: basalioma, carcinoma in situ of the cervix uteri, completely resected melanoma TNMpT1)

6. Pregnancy, lactation, positive pregnancy test

7. Refusal to use effective contraception

8. WHO performance index > 2

9. Long-term ingestion of corticosteroids (e.g. for chronic polyarthritis) or antineoplastic drugs (e.g. methotrexate)

10. Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the trial and to formulate his/her own wishes correspondingly

11. Non compliance: Refusal of blood products during treatment, epilepsy, drug dependency, change of residence abroad, prior cerebral injury or similar circumstances which appear to make protocol treatment or long-term follow-up impossible

12. Antiepileptic treatment

13. General intolerance of any protocol medication

14. Any contraindication for study medication according to the summaries of product information

15. Simultaneous participation in another clinical

16. Institutionalization by law

17. Relation of dependence with the sponsor`s representative / trialist

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hodgkin Disease
• Hodgkin Lymphoma
• Lymphoma

Intervention

Drug:
• prednisone

• vinblastine

• doxorubicin

• gemcitabine

Locations

Country	Name	City	State
Germany	University of Cologne	Cologne

Sponsors (1)

Lead Sponsor	Collaborator
University of Cologne

Country where clinical trial is conducted

Germany,